Serological testing for Lyme disease: current assays, diagnostic performance, and challenges
- 1Department of Pathology, Microbiology and Immunology, Vanderbilt Health, Nashville, Tennessee, USA
Abstract
Lyme disease, caused by Borrelia burgdorferi sensu lato, remains the most common vector-borne infection in temperate regions of the Northern Hemisphere. Laboratory diagnosis relies primarily on serologic testing, as current direct detection methods generally lack sensitivity in routine clinical specimens. Current serological diagnosis of Lyme disease relies on a two-tiered testing algorithm. In the article by E. J. Horn, B. Menefee, A. M. Schotthoefer, G. Dempsey, et al. (J Clin Microbiol 64:e01187-25, 2026, https://doi.org/10.1128/jcm.01187-25), the authors further demonstrated that the modified two-tiered testing (MTTT) algorithm has increased sensitivity compared with the standard two-tiered testing (STTT) algorithm for detecting antibodies from early Lyme disease samples. Despite the improved sensitivity using MTTT, important limitations persist, including limited sensitivity in early infection and the inability to distinguish active from past infection. This commentary briefly summarizes the current landscape of Lyme disease serologic assays, outlines established and emerging diagnostic algorithms, and discusses key challenges that continue to impact diagnostic accuracy and clinical decision-making.
Related
- A blistering neonatal nodule: Diagnostic challenges in cutaneous mastocytoma
- Netherton syndrome presenting with generalized erythroderma in a preterm neonate: Diagnostic and therapeutic challenges.
- Understanding diagnostic challenges and identifying priorities to tackle antimicrobial resistance in conflict zones
- Otoacariasis in East China: a case series of three tick bites with diagnostic and management challenges.
- Cervical leukoplakia in Ghana: Unveiling diagnostic challenges and informing low-resource screening strategies
BibTeX
@article{tao2026serological,
title = {{Serological testing for Lyme disease: current assays, diagnostic performance, and challenges}},
author = {Lili Tao},
journal = {Journal of Clinical Microbiology},
year = {2026},
month = jul,
doi = {10.1128/jcm.00322-26},
url = {https://doi.org/10.1128/jcm.00322-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Serological testing for Lyme disease: current assays, diagnostic performance, and challenges
AU - Lili Tao
PY - 2026
DA - 2026/07/20
JO - Journal of Clinical Microbiology
DO - 10.1128/jcm.00322-26
UR - https://doi.org/10.1128/jcm.00322-26
AB - Lyme disease, caused by Borrelia burgdorferi sensu lato, remains the most common vector-borne infection in temperate regions of the Northern Hemisphere. Laboratory diagnosis relies primarily on serologic testing, as current direct detection methods generally lack sensitivity in routine clinical specimens. Current serological diagnosis of Lyme disease relies on a two-tiered testing algorithm. In the article by E. J. Horn, B. Menefee, A. M. Schotthoefer, G. Dempsey, et al. (J Clin Microbiol 64:e01187-25, 2026, https://doi.org/10.1128/jcm.01187-25), the authors further demonstrated that the modified two-tiered testing (MTTT) algorithm has increased sensitivity compared with the standard two-tiered testing (STTT) algorithm for detecting antibodies from early Lyme disease samples. Despite the improved sensitivity using MTTT, important limitations persist, including limited sensitivity in early infection and the inability to distinguish active from past infection. This commentary briefly summarizes the current landscape of Lyme disease serologic assays, outlines established and emerging diagnostic algorithms, and discusses key challenges that continue to impact diagnostic accuracy and clinical decision-making.
SN - 0095-1137
SN - 1098-660X
ER -